These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 31389190)

  • 1. Fixed-dose combination of umeclidinium and vilanterol for patients with chronic obstructive pulmonary disease: A systematic review.
    Ramadan WH; Al Masri S; Rizk J
    Clin Respir J; 2019 Nov; 13(11):663-673. PubMed ID: 31389190
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evidence-based review of data on the combination inhaler umeclidinium/vilanterol in patients with COPD.
    Albertson TE; Bowman WS; Harper RW; Godbout RM; Murin S
    Int J Chron Obstruct Pulmon Dis; 2019; 14():1251-1265. PubMed ID: 31239659
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety, tolerability, pharmacodynamics and pharmacokinetics of umeclidinium and vilanterol alone and in combination: a randomized crossover trial.
    Kelleher DL; Mehta RS; Jean-Francois BM; Preece AF; Blowers J; Crater GD; Thomas P
    PLoS One; 2012; 7(12):e50716. PubMed ID: 23284643
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative Efficacy of Umeclidinium/Vilanterol Versus Other Bronchodilators for the Treatment of Chronic Obstructive Pulmonary Disease: A Network Meta-Analysis.
    Ismaila AS; Haeussler K; Czira A; Tongbram V; Malmenäs M; Agarwal J; Nassim M; Živković-Gojović M; Shen Y; Dong X; Duarte M; Compton C; Vogelmeier CF; Halpin DMG
    Adv Ther; 2022 Nov; 39(11):4961-5010. PubMed ID: 35857184
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Umeclidinium/vilanterol fixed-dose combination for COPD.
    Gras J
    Drugs Today (Barc); 2014 Mar; 50(3):231-8. PubMed ID: 24696868
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness analysis of umeclidinium/vilanterol for the management of patients with moderate to very severe COPD using an economic model.
    Wilson MR; Patel JG; Coleman A; McDade CL; Stanford RH; Earnshaw SR
    Int J Chron Obstruct Pulmon Dis; 2017; 12():997-1008. PubMed ID: 28392684
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New developments in the combination treatment of COPD: focus on umeclidinium/vilanterol.
    Cazzola M; Segreti A; Matera MG
    Drug Des Devel Ther; 2013; 7():1201-8. PubMed ID: 24143077
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Umeclidinium/Vilanterol: first global approval.
    Scott LJ; Hair P
    Drugs; 2014 Mar; 74(3):389-95. PubMed ID: 24532124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of severe renal impairment on umeclidinium and umeclidinium/vilanterol pharmacokinetics and safety: a single-blind, nonrandomized study.
    Mehta R; Hardes K; Brealey N; Tombs L; Preece A; Kelleher D
    Int J Chron Obstruct Pulmon Dis; 2015; 10():15-23. PubMed ID: 25565796
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population pharmacokinetics of inhaled umeclidinium and vilanterol in patients with chronic obstructive pulmonary disease.
    Goyal N; Beerahee M; Kalberg C; Church A; Kilbride S; Mehta R
    Clin Pharmacokinet; 2014 Jul; 53(7):637-48. PubMed ID: 24756395
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of umeclidinium/vilanterol according to the degree of reversibility of airflow limitation at screening: a post hoc analysis of the EMAX trial.
    Vogelmeier CF; Jones PW; Kerwin EM; Boucot IH; Maltais F; Tombs L; Compton C; Lipson DA; Bjermer LH
    Respir Res; 2021 Oct; 22(1):279. PubMed ID: 34711232
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The combination of umeclidinium bromide and vilanterol in the management of chronic obstructive pulmonary disease: current evidence and future prospects.
    Feldman GJ; Edin A
    Ther Adv Respir Dis; 2013 Dec; 7(6):311-9. PubMed ID: 24004659
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Umeclidinium/vilanterol: a review of its use as maintenance therapy in adults with chronic obstructive pulmonary disease.
    Blair HA; Deeks ED
    Drugs; 2015 Jan; 75(1):61-74. PubMed ID: 25398674
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic effects on treatment response of umeclidinium/vilanterol in chronic obstructive pulmonary disease.
    Condreay L; Huang L; Harris E; Brooks J; Riley JH; Church A; Ghosh S
    Respir Med; 2016 May; 114():123-6. PubMed ID: 27109822
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single-inhaler triple therapy utilizing the once-daily combination of fluticasone furoate, umeclidinium and vilanterol in the management of COPD: the current evidence base and future prospects.
    Malerba M; Nardin M; Santini G; Mores N; Radaeli A; Montuschi P
    Ther Adv Respir Dis; 2018; 12():1753466618760779. PubMed ID: 29537340
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized, parallel-group study to evaluate the efficacy of umeclidinium/vilanterol 62.5/25 μg on health-related quality of life in patients with COPD.
    Siler TM; Donald AC; O'Dell D; Church A; Fahy WA
    Int J Chron Obstruct Pulmon Dis; 2016; 11():971-9. PubMed ID: 27274218
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trelegy Ellipta--a three-drug inhaler for COPD.
    Med Lett Drugs Ther; 2018 May; 60(1547):86-88. PubMed ID: 29913467
    [No Abstract]   [Full Text] [Related]  

  • 18. Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD.
    Lipson DA; Barnhart F; Brealey N; Brooks J; Criner GJ; Day NC; Dransfield MT; Halpin DMG; Han MK; Jones CE; Kilbride S; Lange P; Lomas DA; Martinez FJ; Singh D; Tabberer M; Wise RA; Pascoe SJ;
    N Engl J Med; 2018 May; 378(18):1671-1680. PubMed ID: 29668352
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD.
    Donohue JF; Maleki-Yazdi MR; Kilbride S; Mehta R; Kalberg C; Church A
    Respir Med; 2013 Oct; 107(10):1538-46. PubMed ID: 23830094
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological characterization of the interaction between umeclidinium and vilanterol in human bronchi.
    Calzetta L; Rogliani P; Facciolo F; Rendina E; Cazzola M; Matera MG
    Eur J Pharmacol; 2017 Oct; 812():147-154. PubMed ID: 28716723
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.